MYOK Thx Dew ..I've owned it from $7.50 ..increasing my position over time . Co is based in the Bay Area ( where I reside ) and I'm fortunate to know some one ( Stanford PHD ) who is familiar with top management . I'm also a CAD ( coronary artery disease ) patient with a thickening of the walls of my left ventricle ...so I follow the Co's research.
IMHO this Co will apply for a Break Through Therapy designation . They will meet with the FDA before Oct 10th to discuss the P 2 results and hopefully finalize design of their pivotal trial scheduled late this year , early 2018
There will also be an important readout out on their second candidate MYK491 ...dilated cardiomyopathy ( DCM ) in which there is a serious unmet need and no approved therapies ...in this Qt of 2017 ..its a P1 trial .
There are risks ...will FDA allow them to proceed directly into a pivotal trial or want a P2 b trial run first ( my lay mans take ) ?.....but I suggest those that follow your board, chk the Co out .
News 
Market Data 
Discover 
